Maintaining a healthy weight is good for your body and can also help with self-esteem. If you’ve been trying to lose weight, ...

Novo Nordisk is currently leading the market for incretin therapies with semaglutide-based products Ozempic for type 2 ...

Sociodemographic, health care, and clinical factors are associated with receipt of semaglutide in those with obesity but ...

MALONE — Union officials confirmed that on Wednesday multiple correction officers and staff were recently treated at a ...

Early research suggests GLP-1 drugs could prevent or treat Alzheimer's Disease. Results from a big clinical trial could soon ...

Revlimid, which has arguably been the single biggest growth driver for Dr Reddy's in recent years, is set to go off patent in ...

The long-term prospects for the company are evolving with product approvals in China, build-up of consumer healthcare franchise, and a biosimilar pipeline.

A Medscape survey found that a strong majority of physicians believe high-risk patients should have easier access to new weight loss drugs.

A new report finds half of adults in the United States could be eligible for popular weight loss drugs. KYW medical editor Dr ...

IST, the barometer index, the S&P BSE Sensex, shed 45.42 points or 0.07% to 76,474.96. The Nifty 50 index fell 20.60 points or 0.09% to 23,184.75.

Dr. Reddy’s is focusing on a pipeline of complex drugs, including GLP-1s (such as Semaglutide) as well as biosimilars and consumer care to offset the loss of exclusivity for its blockbuster drug ...

Semaglutide is a powerful aid for managing weight and Type 2 diabetes, but it’s not a free pass to stick with old habits—or skip taking action altogether. If you’ve been struggling with weight loss, ...